Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD ...

The Phase 1 (ACTRN12625000212459p) randomized, double-blind, placebo-controlled, first-in-human study of single ascending doses of ABS-101 will evaluate safety, tolerability, pharmacokinetics (PK), ...

The following is a summary of “Model-informed identification of optimised dosing strategies for meropenem in critically ill ...

Research and development expenses were $6.7 million for the first quarter ended March 31, 2025, compared to $10.4 million in ...

On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to ...

The poster can be accessed on Skye's Spotlight page.

The City of Geneva Police Department posted a ‘quick-fact’ sheet to its Facebook page over the weekend which included the ...

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, I ...

On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 - - Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease ...

RallyBio is steering around more tight corners as it announces a further 40% reduction in staffers just weeks after ...

First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts ...

Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ETCompany ParticipantsJustine Koenigsberg - Vice President ...